{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:47:03Z","timestamp":1791730023954,"version":"4.3.4"},"reference-count":124,"publisher":"SAABRON PRESS","issue":"4","license":[{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>While acknowledging that newer therapies have improved survival rates in chronic lymphocytic leukemia (CLL), patients with high-risk disease features are at an increased risk of treatment failure. Allogeneic hematopoietic cell transplantation (allo-HCT) was traditionally offered as front-line consolidation in high-risk CLL; however, with the emergence of targeted therapies like Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL-2) inhibitors, the role of allo-HCT has been relegated to later stages of the disease. Patients with relapsed\/refractory (R\/R) CLL who have failed both BTK and BCL-2 inhibitors represent a therapeutic challenge owing to a poor prognosis. Chimeric antigen receptor T-cell (CAR T) therapies targeting CD19 have improved response rates and overall survival in various types of R\/R B-cell non-Hodgkin lymphomas. For CLL, no approved CAR T-cell therapies are yet available. Emerging data appear to show a therapeutic benefit of CAR T-cell therapy in patients with R\/R CLL, even after failing an allo-HCT.<\/jats:p>","DOI":"10.46989\/001c.88382","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T12:27:20Z","timestamp":1701174440000},"source":"Crossref","is-referenced-by-count":3,"title":["Chimeric Antigen Receptor T-cell Therapy for Chronic Lymphocytic Leukemia: What is the supporting evidence so far?"],"prefix":"10.46989","volume":"5","author":[{"given":"Razan","family":"Mohty","sequence":"first","affiliation":[{"name":"Department of Blood and Marrow Transplantation and Cellular Immune Therapy, Moffitt Cancer Center, Tampa, Fl, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaykha","family":"Alotaibi","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Gadd","sequence":"additional","affiliation":[{"name":"Regenerative Immunotherapy and CAR-T Translational Research Program, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Luo","sequence":"additional","affiliation":[{"name":"Regenerative Immunotherapy and CAR-T Translational Research Program, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Parrondo","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Qin","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA"},{"name":"Regenerative Immunotherapy and CAR-T Translational Research Program, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2023,11,28]]},"reference":[{"issue":"19","key":"ref1","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1182\/blood.2020005362","article-title":"CAR-T and ibrutinib vs CLL: sequential or simultaneous?","volume":"135","author":"Arnon P. Kater","year":"2020","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"16","key":"ref2","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1182\/bloodadvances.2023010016","article-title":"Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions","volume":"7","author":"Ajay Major","year":"2023","journal-title":"Blood Adv","ISSN":"https:\/\/id.crossref.org\/issn\/2473-9529","issn-type":"print"},{"issue":"1","key":"ref3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13045-021-01209-9","article-title":"Born to survive: how cancer cells resist CAR T cell therapy","volume":"14","author":"Jean Lemoine","year":"2021","journal-title":"Journal of Hematology &amp; Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/1756-8722","issn-type":"print"},{"issue":"6","key":"ref4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.cir-15-0231","article-title":"T Cells Expressing CD19\/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells","volume":"4","author":"Eugenia Zah","year":"2016","journal-title":"Cancer Immunology Research","ISSN":"https:\/\/id.crossref.org\/issn\/2326-6066","issn-type":"print"},{"issue":"10","key":"ref5","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Nirav N. Shah","year":"2020","journal-title":"Nature Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1078-8956","issn-type":"print"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22","volume":"11","author":"Haiying Qin","year":"2018","journal-title":"Molecular Therapy - Oncolytics","ISSN":"https:\/\/id.crossref.org\/issn\/2372-7705","issn-type":"print"},{"issue":"8","key":"ref7","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","volume":"27","author":"Jay Y. Spiegel","year":"2021","journal-title":"Nature Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1078-8956","issn-type":"print"},{"issue":"586","key":"ref8","doi-asserted-by":"publisher","first-page":"eabc6401","DOI":"10.1126\/scitranslmed.abc6401","article-title":"Trispecific CD19-CD20-CD22\u2013targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models","volume":"13","author":"Dina Schneider","year":"2021","journal-title":"Science Translational Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1946-6234","issn-type":"print"},{"issue":"4","key":"ref9","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s41375-021-01477-x","article-title":"CD19\/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia","volume":"36","author":"Xiuli Wang","year":"2022","journal-title":"Leukemia","ISSN":"https:\/\/id.crossref.org\/issn\/0887-6924","issn-type":"print"},{"issue":"1","key":"ref10","doi-asserted-by":"publisher","first-page":"12506","DOI":"10.1038\/s41598-022-16616-2","article-title":"Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells","volume":"12","author":"Li Li","year":"2022","journal-title":"Scientific Reports","ISSN":"https:\/\/id.crossref.org\/issn\/2045-2322","issn-type":"print"},{"issue":"6","key":"ref11","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/s1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"International CLLIPIwg","year":"2016","journal-title":"The Lancet Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/1470-2045","issn-type":"print"},{"issue":"18","key":"ref12","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Hollie J. Pegram","year":"2012","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"2","key":"ref13","doi-asserted-by":"publisher","first-page":"e001229","DOI":"10.1136\/jitc-2020-001229","article-title":"Modulating TNF\u03b1 activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia","volume":"8","author":"Pinar Ataca Atilla","year":"2020","journal-title":"Journal for ImmunoTherapy of Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/2051-1426","issn-type":"print"},{"issue":"13","key":"ref14","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18","volume":"20","author":"Biliang Hu","year":"2017","journal-title":"Cell Reports","ISSN":"https:\/\/id.crossref.org\/issn\/2211-1247","issn-type":"print"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"718686","DOI":"10.3389\/fimmu.2021.718686","article-title":"Gene-Edited Interleukin CAR-T Cells Therapy in the Treatment of Malignancies: Present and Future","volume":"12","author":"Zhengchao Zhang","year":"2021","journal-title":"Frontiers in Immunology","ISSN":"https:\/\/id.crossref.org\/issn\/1664-3224","issn-type":"print"},{"issue":"15","key":"ref16","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1182\/bloodadvances.2022009517","article-title":"Cytotoxicity of the CD3\u00d7CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting","volume":"7","author":"Maissa Mhibik","year":"2023","journal-title":"Blood Adv","ISSN":"https:\/\/id.crossref.org\/issn\/2473-9529","issn-type":"print"},{"issue":"5","key":"ref17","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1182\/blood-2018-02-830992","article-title":"A CD19\/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era","volume":"132","author":"Hannah R. Robinson","year":"2018","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"18","key":"ref18","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Renier J. Brentjens","year":"2011","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"95","key":"ref19","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Michael Kalos","year":"2011","journal-title":"Science Translational Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1946-6234","issn-type":"print"},{"issue":"12","key":"ref20","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor\u2013transduced T cells","volume":"119","author":"James N. Kochenderfer","year":"2012","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"17","key":"ref21","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Conrad Russell Y. Cruz","year":"2013","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"17","key":"ref22","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"Susan O\u2019Brien","year":"2018","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"6","key":"ref23","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/jco.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"James N. Kochenderfer","year":"2015","journal-title":"Journal of Clinical Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0732-183X","issn-type":"print"},{"issue":"10","key":"ref24","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/jco.2015.64.5929","article-title":"Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease","volume":"34","author":"Jennifer N. Brudno","year":"2016","journal-title":"Journal of Clinical Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0732-183X","issn-type":"print"},{"issue":"7","key":"ref25","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1172\/jci86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated \u03ba light chains","volume":"126","author":"Carlos A. Ramos","year":"2016","journal-title":"Journal of Clinical Investigation","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9738","issn-type":"print"},{"issue":"8","key":"ref26","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/j.ymthe.2018.05.018","article-title":"Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy","volume":"26","author":"Mark B. Geyer","year":"2018","journal-title":"Molecular Therapy","ISSN":"https:\/\/id.crossref.org\/issn\/1525-0016","issn-type":"print"},{"issue":"32","key":"ref27","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/jco.20.01467","article-title":"Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy","volume":"38","author":"Kathryn M. Cappell","year":"2020","journal-title":"Journal of Clinical Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0732-183X","issn-type":"print"},{"issue":"12","key":"ref28","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1182\/blood-2017-04-775841","article-title":"Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial","volume":"130","author":"Isabelle Kr\u00e4mer","year":"2017","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"1","key":"ref29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1177\/107327481201900107","article-title":"Hematopoietic stem cell allografting for chronic lymphocytic leukemia: a focus on reduced-intensity conditioning regimens","volume":"19","author":"Mohamed A. Kharfan-Dabaja","year":"2012","journal-title":"Cancer Control","ISSN":"https:\/\/id.crossref.org\/issn\/1073-2748","issn-type":"print"},{"issue":"12","key":"ref30","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.bbmt.2016.09.013","article-title":"Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation","volume":"22","author":"Mohamed A. Kharfan-Dabaja","year":"2016","journal-title":"Biology of Blood and Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/1083-8791","issn-type":"print"},{"issue":"16","key":"ref31","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1182\/bloodadvances.2020001956","article-title":"Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents","volume":"4","author":"Lindsey E. Roeker","year":"2020","journal-title":"Blood Adv","ISSN":"https:\/\/id.crossref.org\/issn\/2473-9529","issn-type":"print"},{"issue":"2","key":"ref32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.hemonc.2017.11.001","article-title":"Reduced intensity is preferred over myeloablative conditioning allogeneic HCT in chronic lymphocytic leukemia whenever indicated: A systematic review\/meta-analysis","volume":"11","author":"Mohamed A. Kharfan-Dabaja","year":"2018","journal-title":"Hematology\/Oncology and Stem Cell Therapy","ISSN":"https:\/\/id.crossref.org\/issn\/1658-3876","issn-type":"print"},{"issue":"1","key":"ref33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/hematology.2021000294","article-title":"Infectious complications and vaccines","volume":"2021","author":"Per Ljungman","year":"2021","journal-title":"Hematology","ISSN":"https:\/\/id.crossref.org\/issn\/1520-4391","issn-type":"print"},{"issue":"26","key":"ref34","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/nejmoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Sattva S. Neelapu","year":"2017","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"10254","key":"ref35","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/s0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Jeremy S Abramson","year":"2020","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"issue":"1","key":"ref36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Rebecca L. Siegel","year":"2023","journal-title":"CA: A Cancer Journal for Clinicians","ISSN":"https:\/\/id.crossref.org\/issn\/0007-9235","issn-type":"print"},{"issue":"1","key":"ref37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/nejmoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Stephen J. Schuster","year":"2019","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"5","key":"ref38","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/nejmoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Shannon L. Maude","year":"2018","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"10299","key":"ref39","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/s0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Bijal D Shah","year":"2021","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"issue":"7","key":"ref40","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/nejmoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Frederick L. Locke","year":"2022","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"10343","key":"ref41","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/s0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Manali Kamdar","year":"2022","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"issue":"1","key":"ref42","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s1470-2045(21)00591-x","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Caron A Jacobson","year":"2022","journal-title":"The Lancet Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/1470-2045","issn-type":"print"},{"issue":"2","key":"ref43","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Nathan Hale Fowler","year":"2022","journal-title":"Nature Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1078-8956","issn-type":"print"},{"issue":"14","key":"ref44","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/nejmoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Michael Wang","year":"2020","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"8","key":"ref45","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/nejmoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"David L. Porter","year":"2011","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"26","key":"ref46","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1200\/jco.2017.72.8519","article-title":"Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor\u2013Modified T Cells After Failure of Ibrutinib","volume":"35","author":"Cameron J. Turtle","year":"2017","journal-title":"Journal of Clinical Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0732-183X","issn-type":"print"},{"issue":"1","key":"ref47","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/nejmoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"John C. Byrd","year":"2013","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"1","key":"ref48","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jtct.2021.10.005","article-title":"Driving Out Chronic Lymphocytic Leukemia With CAR T Cells","volume":"28","author":"Mohamed A. Kharfan-Dabaja","year":"2022","journal-title":"Transplantation and Cellular Therapy","ISSN":"https:\/\/id.crossref.org\/issn\/2666-6367","issn-type":"print"},{"issue":"12","key":"ref49","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1182\/blood.2021011895","article-title":"Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL","volume":"139","author":"Tanya Siddiqi","year":"2022","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"2","key":"ref50","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bjh.18357","article-title":"Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia","volume":"199","author":"Paul J. Hampel","year":"2022","journal-title":"British Journal of Haematology","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1048","issn-type":"print"},{"issue":"Supplement 1","key":"ref51","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1182\/blood-2021-150751","article-title":"Addressing a new challenge in chronic lymphocytic leukemia: outcomes of therapies after exposure to both a covalent Bruton's tyrosine kinase inhibitor and venetoclax","volume":"138","author":"Meghan C. Thompson","year":"2021","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"303","key":"ref52","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"David L. Porter","year":"2015","journal-title":"Science Translational Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1946-6234","issn-type":"print"},{"issue":"12","key":"ref53","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute\u2013Working Group 1996 guidelines","volume":"111","author":"Michael Hallek","year":"2008","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"25","key":"ref54","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Michael Hallek","year":"2018","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"16_suppl","key":"ref55","doi-asserted-by":"publisher","first-page":"7501","DOI":"10.1200\/jco.2023.41.16_suppl.7501","article-title":"Lisocabtagene maraleucel (liso-cel) in R\/R chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): Primary analysis of TRANSCEND CLL 004.","volume":"41","author":"Tanya Siddiqi","year":"2023","journal-title":"Journal of Clinical Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/0732-183X","issn-type":"print"},{"issue":"3","key":"ref56","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/blood.2020006770","article-title":"Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies","volume":"137","author":"Jordan Gauthier","year":"2021","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"11","key":"ref57","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1038\/s41409-021-01420-9","article-title":"Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors","volume":"56","author":"Razan Mohty","year":"2021","journal-title":"Bone Marrow Transplantation","ISSN":"https:\/\/id.crossref.org\/issn\/0268-3369","issn-type":"print"},{"issue":"4","key":"ref58","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/nejmoa1513257","article-title":"Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Andrew W. Roberts","year":"2016","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"9","key":"ref59","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"John C. Riches","year":"2013","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"15","key":"ref60","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Jason A. Dubovsky","year":"2013","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"9","key":"ref61","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Joseph A. Fraietta","year":"2016","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"1","key":"ref62","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies","volume":"17","author":"Simar Pal Singh","year":"2018","journal-title":"Molecular Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1476-4598","issn-type":"print"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"686768","DOI":"10.3389\/fimmu.2021.686768","article-title":"BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects","volume":"12","author":"Marzia Palma","year":"2021","journal-title":"Frontiers in Immunology","ISSN":"https:\/\/id.crossref.org\/issn\/1664-3224","issn-type":"print"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"15330338221133224","DOI":"10.1177\/15330338221133224","article-title":"Synergistic Effects of Zanubrutinib Combined With CD19 CAR-T Cells in Raji Cells in Vitro and in Vivo","volume":"21","author":"Xiupeng Ye","year":"2022","journal-title":"Technology in Cancer Research &amp; Treatment","ISSN":"https:\/\/id.crossref.org\/issn\/1533-0346","issn-type":"print"},{"issue":"19","key":"ref65","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Jordan Gauthier","year":"2020","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"21","key":"ref66","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","article-title":"Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia","volume":"6","author":"Saar Gill","year":"2022","journal-title":"Blood Adv","ISSN":"https:\/\/id.crossref.org\/issn\/2473-9529","issn-type":"print"},{"issue":"Supplement 1","key":"ref67","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2020-140622","article-title":"Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed\/Refractory (R\/R) Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL)","volume":"136","author":"William G. Wierda","year":"2020","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"5","key":"ref68","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Joseph A. Fraietta","year":"2018","journal-title":"Nature Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1078-8956","issn-type":"print"},{"issue":"22","key":"ref69","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/nejmoa1900574","article-title":"Ibrutinib and Venetoclax for First-Line Treatment of CLL","volume":"380","author":"Nitin Jain","year":"2019","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"2","key":"ref70","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/14712598.2020.1822318","article-title":"Anti-CD20 treatment for B-cell malignancies: current status and future directions","volume":"21","author":"Christian Klein","year":"2021","journal-title":"Expert Opinion on Biological Therapy","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2598","issn-type":"print"},{"issue":"20","key":"ref71","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","article-title":"Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance","volume":"113","author":"Junji Hiraga","year":"2009","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"5","key":"ref72","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/nejmoa1817073","article-title":"Ibrutinib\u2013Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia","volume":"381","author":"Tait D. Shanafelt","year":"2019","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"17","key":"ref73","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results","volume":"119","author":"Brian G. Till","year":"2012","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"1","key":"ref74","doi-asserted-by":"publisher","first-page":"16002","DOI":"10.1038\/sigtrans.2016.2","article-title":"Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report","volume":"1","author":"Wen-ying Zhang","year":"2016","journal-title":"Signal Transduction and Targeted Therapy","ISSN":"https:\/\/id.crossref.org\/issn\/2059-3635","issn-type":"print"},{"issue":"10","key":"ref75","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.jcyt.2022.05.001","article-title":"CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory\/relapsed B-cell non-Hodgkin lymphoma","volume":"24","author":"Qian Cheng","year":"2022","journal-title":"Cytotherapy","ISSN":"https:\/\/id.crossref.org\/issn\/1465-3249","issn-type":"print"},{"issue":"6","key":"ref76","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1158\/2326-6066.cir-15-0276","article-title":"Preserved Activity of CD20-Specific Chimeric Antigen Receptor\u2013Expressing T Cells in the Presence of Rituximab","volume":"4","author":"Gregory A. Rufener","year":"2016","journal-title":"Cancer Immunology Research","ISSN":"https:\/\/id.crossref.org\/issn\/2326-6066","issn-type":"print"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3389\/fimmu.2018.02235","article-title":"CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity","volume":"9","author":"Edward A. Clark","year":"2018","journal-title":"Frontiers in Immunology","ISSN":"https:\/\/id.crossref.org\/issn\/1664-3224","issn-type":"print"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2147\/itt.s288546","article-title":"Targeting CD22 for the Treatment of B-Cell Malignancies","volume":"10","author":"Nikesh N Shah","year":"2021","journal-title":"ImmunoTargets and Therapy","ISSN":"https:\/\/id.crossref.org\/issn\/2253-1556","issn-type":"print"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3389\/fonc.2020.00827","article-title":"The TNFSF Members APRIL and BAFF and Their Receptors TACI, BCMA, and BAFFR in Oncology, With a Special Focus in Breast Cancer","volume":"10","author":"Marilena Kampa","year":"2020","journal-title":"Frontiers in Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/2234-943X","issn-type":"print"},{"issue":"22","key":"ref80","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Constantine S. Tam","year":"2022","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.3389\/fimmu.2018.02285","article-title":"BAFF and BAFF-Receptor in B Cell Selection and Survival","volume":"9","author":"Cristian R. Smulski","year":"2018","journal-title":"Frontiers in Immunology","ISSN":"https:\/\/id.crossref.org\/issn\/1664-3224","issn-type":"print"},{"issue":"6","key":"ref82","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.4049\/jimmunol.0800933","article-title":"B cell receptor and BAFF receptor signaling regulation of B cell homeostasis","volume":"183","author":"Wasif N. Khan","year":"2009","journal-title":"The Journal of Immunology","ISSN":"https:\/\/id.crossref.org\/issn\/0022-1767","issn-type":"print"},{"issue":"511","key":"ref83","doi-asserted-by":"publisher","first-page":"eaaw9414","DOI":"10.1126\/scitranslmed.aaw9414","article-title":"CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies","volume":"11","author":"Hong Qin","year":"2019","journal-title":"Science Translational Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1946-6234","issn-type":"print"},{"issue":"10","key":"ref84","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s00262-020-02614-8","article-title":"Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions","volume":"69","author":"Zhenyuan Dong","year":"2020","journal-title":"Cancer Immunology, Immunotherapy","ISSN":"https:\/\/id.crossref.org\/issn\/0340-7004","issn-type":"print"},{"issue":"8","key":"ref85","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1073\/pnas.0712148105","article-title":"Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a","volume":"105","author":"Tetsuya Fukuda","year":"2008","journal-title":"Proceedings of the National Academy of Sciences","ISSN":"https:\/\/id.crossref.org\/issn\/0027-8424","issn-type":"print"},{"issue":"1","key":"ref86","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3390\/cells10010142","article-title":"The WNT\/ROR Pathway in Cancer: From Signaling to Therapeutic Intervention","volume":"10","author":"Kerstin Menck","year":"2021","journal-title":"Cells","ISSN":"https:\/\/id.crossref.org\/issn\/2073-4409","issn-type":"print"},{"issue":"11","key":"ref87","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1084\/jem.194.11.1639","article-title":"Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia","volume":"194","author":"Andreas Rosenwald","year":"2001","journal-title":"The Journal of Experimental Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1540-9538","issn-type":"print"},{"issue":"11","key":"ref88","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1182\/blood.v106.11.2976.2976","article-title":"Immune Therapy for Chronic Lymphocytic Leukemia Induces the Antibody Response Against a Novel Tumor-Associated Antigen, the Orphan Tyrosine Kinase Receptor ROR1.","volume":"106","author":"Tetsuya Fukuda","year":"2005","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"6","key":"ref89","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/leu.2016.368","article-title":"Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib","volume":"31","author":"J Yu","year":"2017","journal-title":"Leukemia","ISSN":"https:\/\/id.crossref.org\/issn\/0887-6924","issn-type":"print"},{"issue":"40","key":"ref90","doi-asserted-by":"publisher","first-page":"10731","DOI":"10.1073\/pnas.1708264114","article-title":"<i>MicroRNA<\/i> dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia","volume":"114","author":"Laura Z. Rassenti","year":"2017","journal-title":"Proceedings of the National Academy of Sciences","ISSN":"https:\/\/id.crossref.org\/issn\/0027-8424","issn-type":"print"},{"issue":"12","key":"ref91","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/nejmoa1713976","article-title":"Venetoclax\u2013Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"378","author":"John F. Seymour","year":"2018","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3389\/fonc.2012.00034","article-title":"ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy","volume":"2","author":"Guilly Rebagay","year":"2012","journal-title":"Frontiers in Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/2234-943X","issn-type":"print"},{"issue":"12","key":"ref93","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1158\/1078-0432.ccr-13-0330","article-title":"Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells","volume":"19","author":"Michael Hudecek","year":"2013","journal-title":"Clinical Cancer Research","ISSN":"https:\/\/id.crossref.org\/issn\/1078-0432","issn-type":"print"},{"issue":"2","key":"ref94","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/2326-6066.cir-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","volume":"3","author":"Michael Hudecek","year":"2015","journal-title":"Cancer Immunology Research","ISSN":"https:\/\/id.crossref.org\/issn\/2326-6066","issn-type":"print"},{"issue":"34","key":"ref95","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1038\/s41388-022-02416-5","article-title":"ROR1-targeting switchable CAR-T cells for cancer therapy","volume":"41","author":"Haiyong Peng","year":"2022","journal-title":"Oncogene","ISSN":"https:\/\/id.crossref.org\/issn\/0950-9232","issn-type":"print"},{"issue":"14","key":"ref96","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1182\/blood-2018-04-842708","article-title":"Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas","volume":"132","author":"Irene Scarf\u00f2","year":"2018","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"8","key":"ref97","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1182\/bloodadvances.2018029678","article-title":"Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma","volume":"3","author":"Hakan K\u00f6ksal","year":"2019","journal-title":"Blood Adv","ISSN":"https:\/\/id.crossref.org\/issn\/2473-9529","issn-type":"print"},{"issue":"7","key":"ref98","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1158\/1535-7163.mct-15-0067","article-title":"AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody\u2013Drug Conjugate as a Potential Therapeutic for B\/T-Cell Malignancies and AML: A New Role for CD37 in AML","volume":"14","author":"Daniel S. Pereira","year":"2015","journal-title":"Molecular Cancer Therapeutics","ISSN":"https:\/\/id.crossref.org\/issn\/1535-7163","issn-type":"print"},{"issue":"24","key":"ref99","doi-asserted-by":"publisher","first-page":"9531","DOI":"10.3390\/ijms21249531","article-title":"CD37 in B Cell Derived Tumors\u2014More than Just a Docking Point for Monoclonal Antibodies","volume":"21","author":"Malgorzata Bobrowicz","year":"2020","journal-title":"International Journal of Molecular Sciences","ISSN":"https:\/\/id.crossref.org\/issn\/1422-0067","issn-type":"print"},{"issue":"15","key":"ref100","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1128\/mcb.20.15.5363-5369.2000","article-title":"Targeted inactivation of the tetraspanin CD37 impairs T-cell-dependent B-cell response under suboptimal costimulatory conditions","volume":"20","author":"Klaus-Peter Knobeloch","year":"2000","journal-title":"Molecular and Cellular Biology","ISSN":"https:\/\/id.crossref.org\/issn\/1098-5549","issn-type":"print"},{"issue":"7","key":"ref101","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1182\/blood-2006-12-062927","article-title":"Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical","volume":"110","author":"Xiaobin Zhao","year":"2007","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"19","key":"ref102","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/nejmoa2213093","article-title":"First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia","volume":"388","author":"Barbara Eichhorst","year":"2023","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"5","key":"ref103","doi-asserted-by":"publisher","first-page":"723","DOI":"10.4161\/mabs.25282","article-title":"Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies","volume":"5","author":"Sarwish Rafiq","year":"2013","journal-title":"MAbs","ISSN":"https:\/\/id.crossref.org\/issn\/1942-0862","issn-type":"print"},{"issue":"3","key":"ref104","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology","volume":"88","author":"Fabio Malavasi","year":"2008","journal-title":"Physiological Reviews","ISSN":"https:\/\/id.crossref.org\/issn\/0031-9333","issn-type":"print"},{"issue":"2","key":"ref105","doi-asserted-by":"publisher","first-page":"827","DOI":"10.4049\/jimmunol.1401350","article-title":"Chronic Lymphocytic Leukemia Cells Express CD38 in Response to Th1 Cell\u2013Derived IFN-\u03b3 by a T-bet\u2013Dependent Mechanism","volume":"194","author":"Simone B\u00fcrgler","year":"2015","journal-title":"The Journal of Immunology","ISSN":"https:\/\/id.crossref.org\/issn\/0022-1767","issn-type":"print"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"113395","DOI":"10.1016\/j.biopha.2022.113395","article-title":"CD38: An important regulator of T cell function","volume":"153","author":"Wentao Li","year":"2022","journal-title":"Biomedicine & Pharmacotherapy","ISSN":"https:\/\/id.crossref.org\/issn\/0753-3322","issn-type":"print"},{"issue":"9","key":"ref107","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/2159-8290.cd-17-1033","article-title":"CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1\/PD-L1 Blockade","volume":"8","author":"Limo Chen","year":"2018","journal-title":"Cancer Discovery","ISSN":"https:\/\/id.crossref.org\/issn\/2159-8274","issn-type":"print"},{"issue":"10","key":"ref108","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1182\/bloodadvances.2019001091","article-title":"Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses","volume":"4","author":"Alak Manna","year":"2020","journal-title":"Blood Advances","ISSN":"https:\/\/id.crossref.org\/issn\/2473-9529","issn-type":"print"},{"issue":"8087","key":"ref109","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/s0140-6736(78)91444-7","article-title":"Chronic lymphocytic leukaemia: Clonal origin in a committed B-lymphocyte progenitor","volume":"312","author":"Philip J Fialkow","year":"1978","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"issue":"12","key":"ref110","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1182\/blood-2006-04-017061","article-title":"T lymphocytes redirected against the \u03ba light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells","volume":"108","author":"Juan Vera","year":"2006","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"21","key":"ref111","doi-asserted-by":"publisher","first-page":"5951","DOI":"10.1158\/1078-0432.ccr-20-2754","article-title":"CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B-cell Malignancies While Sparing a Subset of Normal B Cells","volume":"27","author":"Raghuveer Ranganathan","year":"2021","journal-title":"Clinical Cancer Research","ISSN":"https:\/\/id.crossref.org\/issn\/1078-0432","issn-type":"print"},{"issue":"7","key":"ref112","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1172\/jci86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated \u03ba light chains","volume":"126","author":"Carlos A. Ramos","year":"2016","journal-title":"Journal of Clinical Investigation","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9738","issn-type":"print"},{"issue":"4","key":"ref113","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/nejmoa1509981","article-title":"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"John C. Byrd","year":"2016","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"1","key":"ref114","doi-asserted-by":"publisher","first-page":"25629","DOI":"10.1038\/srep25629","article-title":"CD23 can negatively regulate B-cell receptor signaling","volume":"6","author":"Chaohong Liu","year":"2016","journal-title":"Scientific Reports","ISSN":"https:\/\/id.crossref.org\/issn\/2045-2322","issn-type":"print"},{"issue":"2","key":"ref115","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.1365-2141.1995.tb03314.x","article-title":"The two CD23 isoforms display differential regulation in chronic lymphocytic leukaemia","volume":"89","author":"S. Fournier","year":"1995","journal-title":"British Journal of Haematology","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1048","issn-type":"print"},{"issue":"6","key":"ref116","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cncr.10401","article-title":"The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease","volume":"94","author":"Francesco DiRaimondo","year":"2002","journal-title":"Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0008-543X","issn-type":"print"},{"issue":"18","key":"ref117","doi-asserted-by":"publisher","first-page":"4736","DOI":"10.1182\/blood-2010-10-311845","article-title":"In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor","volume":"117","author":"Greta Maria Paola Giordano Attianese","year":"2011","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"7","key":"ref118","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1080\/10428194.2022.2043299","article-title":"Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia","volume":"63","author":"Sarah Tettamanti","year":"2022","journal-title":"Leukemia &amp; Lymphoma","ISSN":"https:\/\/id.crossref.org\/issn\/1042-8194","issn-type":"print"},{"issue":"13","key":"ref119","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1182\/blood-2016-01-692046","article-title":"Chimeric antigen receptor T cells targeting Fc \u03bc receptor selectively eliminate CLL cells while sparing healthy B cells","volume":"128","author":"Elena Faitschuk","year":"2016","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"10","key":"ref120","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1182\/blood-2008-05-157255","article-title":"Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease","volume":"112","author":"Christian Philipp Pallasch","year":"2008","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"8","key":"ref121","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.4049\/jimmunol.1100532","article-title":"TOSO, the Fcmicro receptor, is highly expressed on chronic lymphocytic leukemia B cells, internalizes upon IgM binding, shuttles to the lysosome, and is downregulated in response to TLR activation","volume":"187","author":"B\u00e9reng\u00e8re Vire","year":"2011","journal-title":"The Journal of Immunology","ISSN":"https:\/\/id.crossref.org\/issn\/0022-1767","issn-type":"print"},{"issue":"Supplement 1","key":"ref122","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1182\/blood-2022-159497","article-title":"Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed \/ Refractory CLL\/SLL: Additional Patients and Extended Follow-up from the Phase 1\/2 BRUIN Study","volume":"140","author":"Anthony R. Mato","year":"2022","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"issue":"10","key":"ref123","doi-asserted-by":"publisher","first-page":"668.e1","DOI":"10.1016\/j.jtct.2022.07.009","article-title":"Impact of Rituximab and Corticosteroids on Late Cytopenias Post-Chimeric Antigen Receptor T Cell Therapy","volume":"28","author":"Madiha Iqbal","year":"2022","journal-title":"Transplantation and Cellular Therapy","ISSN":"https:\/\/id.crossref.org\/issn\/2666-6367","issn-type":"print"},{"issue":"4","key":"ref124","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/nejmoa2211582","article-title":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"388","author":"Jennifer R. Brown","year":"2023","journal-title":"New England Journal of Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/88382-chimeric-antigen-receptor-t-cell-therapy-for-chronic-lymphocytic-leukemia-what-is-the-supporting-evidence-so-far","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:09:07Z","timestamp":1791727747000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/88382-chimeric-antigen-receptor-t-cell-therapy-for-chronic-lymphocytic-leukemia-what-is-the-supporting-evidence-so-far"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":124,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.88382","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,28]]}}}